We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Corning Introduces New 1536-well Spheroid Microplate

Corning Introduces New 1536-well Spheroid Microplate content piece image
Spheroid Cell Culture
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute
Corning Incorporated has expanded its spheroid microplate product offerings with the introduction of a unique 1536-well plate designed specifically for growing spheroid cell cultures. The Corning® 1536-well Spheroid Microplate helps scientists generate a higher volume of spheroids for high-throughput screening, which is especially beneficial in cancer research and drug testing.

To help streamline work with 3D cell cultures in an automated environment, the 1536-well spheroid microplate features a novel and proprietary design that allows scientists to generate, culture, assay, and analyze 3D multicellular spheroids in one microplate. The spheroid microplate eliminates the need for a transfer step in visualization or biochemical assays, reducing the risk of cell damage or loss. The newer spheroid microplate format, in addition to Corning’s current 96- and 384-well formats, is compatible with most high-throughput screening instruments.

As with all Corning spheroid microplates, the 1536-well microplate features round well bottoms and a Corning Ultra-Low Attachment (ULA) surface coating to enable uniform, centered, single-spheroid formation across all wells with a simple and easy to use “plug and play” protocol. It is also optimized for visualization with an optically clear well-bottom and black opaque microplate body to reduce well-to-well crosstalk.

“The 1536-well format takes spheroid plates out of the research lab and into high-throughput screening,” said Dr. Keith R. Olson, global director of business operations for Corning Life Sciences. “This enables researchers to drive a larger volume of compounds through drug screening in less time, using a more physiologically relevant 3D cell culture and thereby potentially accelerating the research and drug discovery process.”

Corning continues to advance the science of 3D cell culture by bringing to market innovative solutions that provide easier access to in vivo-like 3D models, such as spheroid microplates, Corning Matrigel® matrix, and Transwell® permeable supports. Corning is committed to providing solutions for researchers in critical areas like cancer biology, tissue engineering, and regenerative medicine to help them bring safe, effective drugs and therapies to market in less time with greater certainty.